X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA IPCA LABS SHASUN PHARMA/
IPCA LABS
 
P/E (TTM) x 123.9 27.7 448.0% View Chart
P/BV x 8.5 2.1 402.3% View Chart
Dividend Yield % 0.2 0.2 96.2%  

Financials

 SHASUN PHARMA   IPCA LABS
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
IPCA LABS
Mar-17
SHASUN PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs94643 14.7%   
Low Rs46503 9.1%   
Sales per share (Unadj.) Rs214.2254.4 84.2%  
Earnings per share (Unadj.) Rs5.316.1 33.2%  
Cash flow per share (Unadj.) Rs15.829.8 53.1%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %1.40.2 819.6%  
Book value per share (Unadj.) Rs53.3194.6 27.4%  
Shares outstanding (eoy) m56.62126.20 44.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.3 14.5%   
Avg P/E ratio x13.135.7 36.7%  
P/CF ratio (eoy) x4.419.2 23.0%  
Price / Book Value ratio x1.32.9 44.5%  
Dividend payout %18.76.2 301.2%   
Avg Mkt Cap Rs m3,95872,300 5.5%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m2,1646,960 31.1%   
Avg. sales/employee Rs ThNM2,413.5-  
Avg. wages/employee Rs ThNM523.2-  
Avg. net profit/employee Rs ThNM152.4-  
INCOME DATA
Net Sales Rs m12,12732,106 37.8%  
Other income Rs m229226 101.6%   
Total revenues Rs m12,35632,332 38.2%   
Gross profit Rs m1,0094,448 22.7%  
Depreciation Rs m5941,730 34.3%   
Interest Rs m415241 172.4%   
Profit before tax Rs m2302,703 8.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73675 -10.8%   
Profit after tax Rs m3022,028 14.9%  
Gross profit margin %8.313.9 60.1%  
Effective tax rate %-31.725.0 -126.7%   
Net profit margin %2.56.3 39.4%  
BALANCE SHEET DATA
Current assets Rs m6,88417,340 39.7%   
Current liabilities Rs m8,4569,559 88.5%   
Net working cap to sales %-13.024.2 -53.5%  
Current ratio x0.81.8 44.9%  
Inventory Days Days62100 61.4%  
Debtors Days Days10857 189.1%  
Net fixed assets Rs m4,97020,779 23.9%   
Share capital Rs m113252 44.9%   
"Free" reserves Rs m2,87524,499 11.7%   
Net worth Rs m3,02024,553 12.3%   
Long term debt Rs m1,8173,517 51.7%   
Total assets Rs m13,34739,595 33.7%  
Interest coverage x1.612.2 12.7%   
Debt to equity ratio x0.60.1 420.0%  
Sales to assets ratio x0.90.8 112.1%   
Return on assets %5.45.7 93.8%  
Return on equity %10.08.3 121.1%  
Return on capital %13.310.5 127.0%  
Exports to sales %46.448.6 95.3%   
Imports to sales %14.214.2 100.1%   
Exports (fob) Rs m5,62215,617 36.0%   
Imports (cif) Rs m1,7284,571 37.8%   
Fx inflow Rs m5,84315,617 37.4%   
Fx outflow Rs m2,1735,828 37.3%   
Net fx Rs m3,6699,790 37.5%   
CASH FLOW
From Operations Rs m3982,764 14.4%  
From Investments Rs m-1,635-1,432 114.2%  
From Financial Activity Rs m1,309-1,591 -82.2%  
Net Cashflow Rs m71-259 -27.5%  

Share Holding

Indian Promoters % 39.2 45.9 85.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 11.4 31.6%  
FIIs % 17.6 25.3 69.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 17.4 227.6%  
Shareholders   20,750 36,892 56.2%  
Pledged promoter(s) holding % 12.3 2.1 574.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   SUVEN LIFE  ORCHID PHARMA LTD  NOVARTIS  TTK HEALTHCARE  SUN PHARMA  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS